Apurva Pandey, MD
Medical Oncology · Portland, ORNPI 1023351137
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $236 of the $263 with a category attached, or 89.7%. AstraZeneca accounts for 89.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $236 and has fallen 93.6% since, to $15 in 2024. That places this record below the midpoint for medical oncology clinicians in OR, where the typical reported total is $810.
Across 4 payments — averaging $65.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$236
- AVEO Pharmaceuticals, Inc.$15
- Gilead$12
Across 34 payments — averaging $16,558 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$268K
- Astrazeneca UK Limited$137K
- Eli Lilly$99K
- AstraZeneca$45K
- AbbVie$15K
What the payments were for
- Food & beverage$23690%
- Education$2710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $236 |
| AVEO Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $12 |
How this compares
$263 in reported general payments places this provider in the 30th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 30 | $441,891 |
| IbrancePalbociclib | 25 | $372,469 |
| Lenalidomide | 21 | $268,451 |
| CabometyxCabozantinib S-Malate | 11 | $258,769 |
| KisqaliRibociclib Succinate | 11 | $160,300 |
| EliquisApixaban | 37 | $33,764 |
| Abiraterone Acetate | 16 | $25,076 |
| Tamoxifen Citrate | 178 | $5,821 |
| Letrozole | 154 | $4,836 |
| Estradiol | 30 | $4,231 |
| Exemestane | 36 | $3,626 |
| Anastrozole | 102 | $2,755 |
| Hydroxyurea | 29 | $554 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $529 |
| Prochlorperazine Maleate | 23 | $497 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Portland
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
- Hagen KenneckePortland$53K
- Adel KardoshPortland$51K
- Brendan CurtiPortland$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.